Please check your internet connection and try again.
## Clobazam (Oral Formulation)
### Overview
Clobazam is a benzodiazepine derivative used as an adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) in pediatric and adult patients.
### Primary Indications
Adjunctive therapy for seizures in Lennox-Gastaut Syndrome (LGS).
### Adult Dosing
* **Initiation:** 5 mg twice daily.
* **Titration:** Increase dose by 5 mg every week as needed and tolerated, up to a maximum of 20 mg twice daily.
### Pediatric Dosing
* **Initiation (Age 2 to <10 years):** 2.5 mg twice daily.
* **Titration (Age 2 to <10 years):** Increase dose by 2.5 mg every week as needed and tolerated, up to a maximum of 10 mg twice daily.
* **Initiation (Age 10 years and older):** 5 mg twice daily.
* **Titration (Age 10 years and older):** Increase dose by 5 mg every week as needed and tolerated, up to a maximum of 20 mg twice daily.
* **Note:** Pediatric dosing may require more frequent adjustments based on weight and clinical response.
### Dose Adjustments
* **Hepatic Impairment:** Use with caution; no specific dose adjustment guidelines are established, but lower doses may be necessary.
* **Renal Impairment:** Use with caution; no specific dose adjustment guidelines are established, but lower doses may be necessary.
### Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
### Adverse Effects
* **Common:** Somnolence, decreased appetite, constipation, aggression, irritability, fatigue, vomiting, upper respiratory tract infection, drooling.
* **Serious:** Severe skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis), paradoxical reactions (e.g., excitation, hallucinations), respiratory depression, dependence, withdrawal symptoms.
### Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other benzodiazepines):** Increased risk of sedation, respiratory depression, and coma.
* **CYP2C19 Inhibitors (e.g., fluconazole, omeprazole):** May increase clobazam concentrations, potentially increasing adverse effects.
* **CYP2C19 Inducers (e.g., rifampin):** May decrease clobazam concentrations, potentially reducing efficacy.
* **Antiepileptic Drugs (AEDs):** Monitor for potential additive CNS depression and interactions affecting AED efficacy.
### Monitoring
* Monitor for therapeutic response (reduction in seizure frequency).
* Monitor for adverse effects, especially somnolence, behavioral changes, and signs of severe skin reactions.
* Monitor for signs of withdrawal upon discontinuation.
### Clinical Pearls
* Clobazam is typically used as adjunctive therapy and should not be used as monotherapy for seizures.
* Dosing should be individualized and titrated slowly to minimize adverse effects.
* Patients and caregivers should be advised of the risk of somnolence and to avoid activities requiring mental alertness until the effects are known.
* Sudden discontinuation can lead to withdrawal symptoms; gradual tapering is recommended.
* Be aware of the potential for serious skin reactions and counsel patients to seek immediate medical attention if a rash develops.
***
*This information is intended for healthcare professionals. It is essential to consult the official prescribing information and relevant clinical guidelines for complete details and to ensure patient-specific care. Dosing may vary based on local protocols and individual patient factors.*
